Effect of DMR in the Treatment of NASH (DMR_NASH_001)

February 24, 2021 updated by: Erasme University Hospital

Evaluation of Duodenal Mucosal Resurfacing (DMR) for the Treatment of Non Alcoholic Steatohepatitis (NASH), a Proof of Concept Study

Non-alcoholic fatty liver disease (NAFLD) is a frequent disease affecting up to 25% of the USA population, 2-44% in Europe and up to 42,6-69,5% in patients with type 2 diabetes. It is a disease that could progress from simple steatosis to non-alcoholic steatohepatitis (NASH), hepatic cirrhosis and hepatocarcinoma. NASH is part of continuum of metabolic syndrome and constitutes a serious public health concern manifesting by premature cardiovascular disease, end stage diabetes complication and will likely become the first cause of end stage liver disease. Insuline resistance is the hallmark of NASH. Some recent studies both in animals and humans have demonstrated abnormal hypertrophy of the duodenal mucosa, changes in enteroendocrine cell density and number, endocrine hyperplasia, and alterations in gut hormone signaling highlighting the role of the upper intestine gut in glucose homeostasis and thus insulin sensitizing. Given these physiological and pathophysiological features, abrasion of duodenal mucosa was assessed both in animals and humans. The investigators reported an improvement in both glucose homeostasis and transaminases levels suggesting possibly an improvement of NASH. Until now, lifestyle medication is the only recognized efficient treatment for fatty liver disease. Unfortunately, only a minority of patients achieve a significant weight loss and lifestyle modifications. The investigators aim to study the duodenal mucosal resurfacing procedure in patients with NASH biopsy proven in a proof of concept study allowing to assess this technique as a potential treatment to NASH.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Introduction

Non-alcoholic fatty liver disease (NAFLD) is a frequent disease affecting up to 25% of the USA population, 2-44% in Europe and up to 42,6-69,5% in patients with type 2 diabetes. It is a disease that could progress from simple steatosis to non-alcoholic steatohepatitis (NASH), hepatic cirrhosis and hepatocarcinoma. NASH is part of continuum of a metabolic syndrome and constitutes a serious public health concern, manifesting by premature cardiovascular disease, end stage diabetes complication and will likely become the first cause of end stage liver disease.

Insulin resistance is the hallmark of NASH. Some recent studies both in animals and humans have demonstrated abnormal hypertrophy of the duodenal mucosa, changes in enteroendocrine cell density and number, endocrine hyperplasia, and alterations in gut hormone signaling highlighting the role of the upper intestine gut in glucose homeostasis and thus insulin sensitizing.

Given these physiological and pathophysiological features, abrasion of duodenal mucosa was assessed both in animals and humans. The investigators reported an improvement in both glucose homeostasis and transaminases levels suggesting possibly an improvement of NASH.

Until now, lifestyle medication is the only recognized efficient treatment for fatty liver disease. Unfortunately, only a minority of patients achieve a significant weight loss and lifestyle modifications.

The investigators aim to study the duodenal mucosal resurfacing procedure in patients with NASH biopsy proven in a proof of concept study allowing to assess this technique as a potential treatment to NASH.

Design of study The study is designed as a single arm, proof of concept, non-randomized, open label trial to be conducted at one investigational site. All patients with biopsy proven NASH will undergo an upper endoscopy to perform a duodenal mucosal resurfacing procedure. Evolution of liver steatosis (assessed by MRI), insulin resistance (assessed by oral glucose tolerance test), liver damage (evaluated by blood tests), liver elastography (assessed by fibroscan, fibrotest), biometric parameters will be performed pre- and post-procedure.

Primary outcome :

- Feasability and safety of duodenal mucosal resurfacing, using Revita ™ duodenal mucosal resurfacing after submucosal injection, in patients with NASH.

Secondary outcomes:

  • Evolution of steatosis assessed by MRI 6 months after the procedure.
  • Evolution of liver fibrosis (assessed by Fibroscan, Fibrotest, Fibrosis four score (FIB-4) and NAFLD fibrosis score) at 6 and 12 months after the procedure.
  • Evolution of liver tests at 6 and 12 months after the procedure.
  • Evolution of insulin resistance at 1,3,6 and 12 months after the procedure.

Study Type

Interventional

Enrollment (Actual)

14

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Belgium
      • Brussels, Belgium, 1070
        • Erasme Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

24 years to 71 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Adult subjects (male and female), age 28 to 75 years.

  2. NASH histological diagnosis according to the currently accepted definition of both EASL and AASLD, requiring the combined presence of steatosis (any degree> 5%) + lobular inflammation of any degree + liver cell ballooning of any amount, on a liver biopsy performed ≤ 6 months before screening in the study and confirmed by central reading during the periode and (apendix 1)

    1. SAF (steatosis, activity, fibrosis) activity score of 3 or 4 (>2)
    2. SAF steatosis score ≥ 1
    3. SAF fibrosis score < 4
  3. No other causes of chronic liver disease and compensated liver disease.
  4. If applicable, have a type 2 diabetes with HbA1c <10.0 %
  5. BMI (body mass index) ≥ 24 and ≤ 40 kg/m2.
  6. Willing to sign an informed consent form.
  7. Willing to comply with study requirements

Exclusion Criteria:

  1. Evidence of another cause of liver disease.
  2. History of sustained alcohol ingestion defined as: daily alcohol consumption > 30 g/day for males and > 20 g/day for females.
  3. Previous gastrointestinal surgery such as subjects who have had Billroth 2, Roux-en-Y gastric bypass, or other similar procedures or conditions.
  4. Known autoimmune disease, including celiac disease, or symptoms of systemic lupus eythematosus, sleroderma or other auto-immune connective tissue disorder.
  5. For type 2 diabetes subjects, no current use of insulin or GLP-1 analogues.
  6. Type 1 diabetes.
  7. Probable insulin production failure defined as fasting C peptide serum < 1 ng/ml.
  8. History of acute or chronic pancreatitis.
  9. Active malignancy.
  10. Persistent anemia defined as Hb < 10 g/dl.
  11. Use of anticoagulation therapy which cannot be discontinued for 7 days before and 14 days after the procedure.
  12. Use of P2Y12 inhibitors (clopidrogel, prasugrel, ticagrelor) which cannot be discontinued for 14 days before and14 days after the procedure.
  13. History of coagulopathy or upper gastro-intestinal bleeding conditions likely to bleed.
  14. Taking corticosteroids or drugs which possibly affect gastrointestinal motility or liver.
  15. Unable to discontinue NSAIDs (non-steroidal anti- inflammatory drugs) during the treatment up to 4 weeks after procedure.
  16. Use of weight loss medications.
  17. Presence of liver cirrhosis (defined by histology)
  18. Platelet count < 120 x 109/L.
  19. Clinical evidence of hepatic decompensation or severe liver impairment as defined by the presence of any of the following abnormalities:
  20. Serum albumin < 32 g/L.
  21. INR> 1.3.
  22. Direct bilirubin> 1.3 mg/L.
  23. ALT or AST > 5x ULN.
  24. Alkaline Phosphatase > 3x ULN.
  25. History of esophageal varices, ascites or hepatic encephalopathy.
  26. Splenomegaly.
  27. Human immunodeficiency virus.
  28. Contraindications to MRI as defined below.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: DMR procedure
Device: DMR

Procedure: DMR Procedure The Fractyl DMR procedure using the Revita System utilizes an over the wire endoscopic approach to ablate the duodenum. The procedure may be completed in an endoscopic suite or in an operating room depending on the facilities and support at each investigative site. All subjects are monitored and anesthetized by conscious sedation per each facility's standard protocol. A full DMR procedure is defined as 5 complete ablations or 9 axial centimeters of circumferentially ablated tissue in the duodenum. Subjects who do not receive any ablations during the DMR procedure will be followed for safety through the 4 week visit and then discontinued from the study.

Other Names:

DMR Revita

Other Names:
  • Revita

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Safety of duodenal mucosal resurfacing characterized by the incidence of all Adverse Device Effects (ADEs), and subsequent adverse events [ Time Frame: 12 months ] in patients with NASH.
Time Frame: 12 months

Safety will be characterized by the incidence of all Adverse Device Effects (ADEs), non-serious and serious, possibly related to or related to the procedure and/or device that are experienced by study participants.

Safety evaluations will also be performed to ensure no subsequent adverse events have occurred and to ensure any adverse events during the trial that are considered on-going are stable or have resolved. Safety will be assessed at 1 and 6 months following the intervention.
12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Magnetic Resonance Fat Fraction (MRFF) from baseline in the following 6 months in DMR subjects.
Time Frame: baseline and 6 months post-procedure
Magnetic Resonance Fat fraction
baseline and 6 months post-procedure
Change in NAS score from baseline in the following 12 months in DMR subjects.
Time Frame: baseline and 12 months post-procedure

Centrally scored histological improvement in NAFLD from baseline to the end of 12 months post-procedure, where improvement is defined as:

  • No worsening in fibrosis; and
  • A decrease in NAFLD Activity Score (NAS) of at least 2 points
baseline and 12 months post-procedure
Change in Fibrosis-4 Index for Liver Fibrosis (FIB-4) from baseline in the following at 6 months in DMR subjects
Time Frame: baseline and 6 months post-procedure
Absolute change in Fibrosis-4 Index for Liver Fibrosis (FIB-4) is a fibrosis marker. A score <1.45 has a negative predictive value of over 90% for advanced liver fibrosis. A score of >3.25 has a positive predictive value of 65% for advanced fibrosis with a specificity of 97%.
baseline and 6 months post-procedure
Change in Fibrosis-4 Index for Liver Fibrosis (FIB-4) from baseline in the following at 12 months in DMR subjects
Time Frame: baseline and 12 months post-procedure
Absolute change in Fibrosis-4 Index for Liver Fibrosis (FIB-4) is a fibrosis marker. A score <1.45 has a negative predictive value of over 90% for advanced liver fibrosis. A score of >3.25 has a positive predictive value of 65% for advanced fibrosis with a specificity of 97%.
baseline and 12 months post-procedure
Change in Transient Elastography using Firboscan from baseline in the following at 6 months in DMR subjects
Time Frame: baseline and 6 months post-procedure
Transient Elastography
baseline and 6 months post-procedure
Change in Transient Elastography using Firboscan from baseline in the following at 12 months in DMR subjects
Time Frame: baseline and 12 months post-procedure
Transient Elastography
baseline and 12 months post-procedure
Change in Magnetic Resonance Fat Fraction (MRFF) from baseline in the following 12 months in DMR subjects.
Time Frame: baseline and 12 months post procedure
Magnetic Resonance Fat fraction
baseline and 12 months post procedure
Change in transaminases levels from baseline in the following 6 months in DMR subjects
Time Frame: baseline and 6 months post-procedure
Transaminases levels
baseline and 6 months post-procedure
Change in transaminases levels from baseline in the following 12 months in DMR subjects
Time Frame: baseline and 12 months post-procedure
Transaminases levels
baseline and 12 months post-procedure
Change in Insulin resistance measured by oral glucose tolerance test (OGTT) from baseline in the following 6 months in DMR subjects
Time Frame: baseline and 6 months post-procedure
Insulin resistance as abnormal HOMA IR
baseline and 6 months post-procedure
Change in Insulin resistance measured by oral glucose tolerance test (OGTT) from baseline in the following 12 months in DMR subjects
Time Frame: baseline and 12 months post procedure
Insulin resistance as abnormal HOMA IR
baseline and 12 months post procedure
Change in stage of fibrosis from baseline in the following 12 months in DMR subjects
Time Frame: baseline and 12 months post-procedure
Liver histology
baseline and 12 months post-procedure

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Erasme University Hospital

Collaborators

Fractyl Laboratories, Inc.

Investigators

  • Principal Investigator: Jacques Deviere, PhD, MD, Erasme Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 8, 2017

Primary Completion (Actual)

July 15, 2020

Study Completion (Actual)

December 31, 2020

Study Registration Dates

First Submitted

April 13, 2018

First Submitted That Met QC Criteria

May 14, 2018

First Posted (Actual)

May 25, 2018

Study Record Updates

Last Update Posted (Actual)

February 25, 2021

Last Update Submitted That Met QC Criteria

February 24, 2021

Last Verified

February 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • P2017/302

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on NASH - Nonalcoholic Steatohepatitis

Clinical Trials on DMR

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hungary

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe